medigraphic.com
Patología Revista Latinoamericana

2009, Número 1

<< Anterior Siguiente >>

Patol Rev Latinoam 2009; 47 (1)


Diagnóstico histopatológico e inmunohistoquímico del linfoma de Hodgkin y su diagnóstico diferencial

Lara-Torres C, Ortiz-Hidalgo C

Idioma: Español
Referencias bibliográficas: 55
Paginas: 35-45
Archivo PDF: 242.48 Kb.


RESUMEN

La clasificación actual del linfoma de Hodgkin está basada en la propuesta por Lukes y Butler en 1966; ha tenido pocos cambios desde entonces. El diagnóstico de linfoma de Hodgkin clásico requiere identificar células de Reed-Sternberg en el entorno celular apropiado y con características inmunohistoquímicas propias; es decir, que las células de Reed-Sternberg sean positivas al CD30, al CD15 y negativas para el CD45 y el EMA, y en ocasiones positivas a marcadores B. La inmunomarcación, además de ayudar al diagnóstico preciso del linfoma de Hodgkin, ha contribuido a diferenciarlo de diversas entidades con las que se puede confundir desde el punto de vista histológico, como el linfoma T periférico (LTP), el linfoma B rico en células T / rico en histiocitos (LBRCTH), el linfoma de células grandes B primario mediastinal (tímico), el linfoma anaplásico de células grandes (LACG), la linfadenopatía reactiva de origen viral (mononucleosis infecciosa), las metástasis (melanoma, tumor de células germinales y algunos sarcomas).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ortiz-Hidalgo C. A short history of Hodgkin’s disease and Burkitt’s lymphoma. Am J Clin Pathol 1994;10 (Suppl. 1):S27- S33.

  2. Forteza J. Hematopathology; a leap forward in pathology. A personal view. Sem Diag Pathol 2008;25:166-77.

  3. Taylor CR. A History of the Reed- Sternberg cell. Biomedicine 1978; 28; 96-203.

  4. Stein H. Introduction. Hodgkin Lymphoma. In: Swerldow SH, Campo E, Harris NL, Jaffe ES, et al. WHO Classifi cation of tumours of haematopoietic and lymphoid tissue. IARC, Lyon 2008; p:321.

  5. Taylor CR. Hodgkin’s disease is a non-Hodgkin lymphoma. Hum Pathol 2005;36:1-4.

  6. Butler JJ. The histological diagnosis of Hodgkin’s disease. Sem Diag Pathol 1992;9:252-6.

  7. Poppema S, Delsol G, Pilieri SA, et al. Nodular lymphocyte predominant Hodgkin lymphoma.In: Swerldow SH, Campo E, Harris NL, Jaffe ES, et al. WHO Classifi cation of tumours of haematopoietic and lymphoid tissue. IARC, Lyon 2008; 323- 5.

  8. Stein H, Delsol G, Pilieri SA. Weiss LM, Popema S, Jaffe ES. Classical Hodgkin Lymphoma. Introduction In: Swerldow SH, Campo E, Harris NL, Jaffe ES, et al. WHO Classifi cation of tumors of hematopoietic and lymphoid tissue. IARC, Lyon 2008; pp:326-9.

  9. Fung HC, Nademanee AP. Approach to Hodgkin’s lymphoma in the new millennium. Hematol Oncol 2002;20;1-15.

  10. Harris NL, Jaffe ES, Stein H et al. A revised European- American classifi cation of lymphoid neoplasms; A proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-92.

  11. Schmitz KR, Distler V, Renné C, Bräuninger A, Hansmann ML. Pathogenesis of Hodgkin’s lymphoma. Eur J Haematol 2005;75;26-33.

  12. Quintanilla-Martinez L, Gamboa-Domínguez A, Gamez-Ledesma I, Ángeles-Ángeles A, Mohar A. Association of Epstein Barr virus latent membrane protein and Hodgkin’s disease in Mexico. Mod Pathol 1995;8:675-9.

  13. Higgins RA, Blankenship JE, Kinney MC. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med 2008;132:441-61.

  14. Pilieri SA, Ascani S, Leoncini L, et al. Hodgkin’s lymphoma: the pathologist’s viewpoint. J Clin Path 2002;55;162-76.

  15. Gruss H-J, Pinto A, Duyster J, Popemma S, Herrman F. Hodgkin’s disease: a tumor with disturbed immunological pathways. Immunol Today 1997;18;156-63.

  16. Hus S-M, Waldron Jr. JW, Hus P-L, Hough Jr. AJ. Cytokines in malignant lymphomas: review and prospective evaluation. Hum Pathol 1993;24:1040-57.

  17. Stein H, Hummel M. Hodgkin’s disease biology and origin of Hodgkin and Reed-Sternberg cells. Cancer Treat Rev 1999;25;161-8.

  18. Hudson MM, Donaldson SS. Hodgkin’s disease. Pediatr Oncol 1997;44;891-906.

  19. Strickler JG, Michie SA, Waranke RA Dorfman RF. The “syncycial variant” of nodular sclerosing Hodgkin’s disease. Am J Surg Pathol 1986;10;170-7.

  20. Van Spronsen DJ, Vrints LW, Hofstra G, Crommelin MA, et al. Disappearance of prognostic signifi cance of histopathological grading of nodular sclerosing Hodgkin’s disease for unselected patients. Br J Haematol 1997;69;322-7.

  21. Doggett RS, Colby TV, Dorfman RA. Interfollicular Hodgkin’s disease. A. J Surg Pathol 1983;78:22-28.

  22. Ashton-Key M, Thorpe PA, Allen JP, Isaacson PG. Follicular Hodgkin’s disease. Am J Surg Pathol 1995;19:1294-9.

  23. Fraga M, Forteza J. Diagnosis of Hodgkin’s disease; an update of histological and immunophenotypical features. Histol Histopathol 2007;22:923-35.

  24. Sextro M, Diehl V, Franklin J,, et al. Lymphocyte predominanceHodgkin’s disease-A workshop report. European Task Force on Lymphoma Ann Oncol 1996;7:61-65.

  25. Harris NL. The many faces of Hodgkin’s disease around the world; what have we learned from its pathology. Ann Oncol 1998;9:S45-S56.

  26. Rahemtullah A, Lee Harris N, Dorn ME, Preffer FI, Hasserjian RP. Beyond the lymphocyte predominant cell: CD4+CD8+ Tcells in nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymphoma 2008;49:1870-8.

  27. Illés A, Simon Z, Tóth E, Rosta A, Miltényi Z, Molnár Z. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-Clinicopathological features based on the data of two Hungarian lymphoma centres. Pathol Oncol Res 2008 Apr 23. [Epub ahead of print].

  28. Medeiros LJ, Elenitoba-Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol. 2007;127:707-22.

  29. Poppema S. Lymphocyte-predominance Hodgkin’s disease. Sem Diag Pathol 1992;9;257-64.

  30. Von Wasielewski R, Mengel M, Fischer R, Hansmann M-L, et al. Classical Hodgkin’s disease. Clinical impact of the Immunophenotype. Am J Pathol 1997;151:1123-30.

  31. Horie R, Watanabe T. CD30 expression and function in health and disease. Immunology 1998;10;457-70.

  32. Aber DA, Weiss LM. CD15: A review. Appl Immunohistochem 1993;1;17-30.

  33. Delsol G, Megetto F, Brousset P, et al. Relation of follicular dendritic cells to Reed-Sternberg cells of Hodgkin’s disease with emphasis on the expression of CD21 antigen. Am J Pathol 1993;142:1729-38.

  34. Unger PD, Strauchen JA. Hodgkin’s disease in AIDS patients. Cancer 1986;58;821-5.

  35. Weiss LM, Chang KL. Association of the Epstein-Barr virus with hematolymphoid neoplasia Adv Anat Pathol 1996;3:1-15.

  36. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.

  37. Marish A, Weisenberger D, Duggan M, et al. Epstein-Barr viral genome in lymph nodes from patients with Hodgkin’s disease may not be specifi c to Reed-Sternberg cells. Am J Pathol 1991;139:37-43.

  38. Vose JM. Peripheral T-cell non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2008;22:997-1005.

  39. Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology fi ndings and clinical outcomes. J Clin Oncol 2008;26:4124-30.

  40. El Weshi A, Akhtar S, Mourad WA, et al. T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma 2007;48:1764-73.

  41. Leoncini L, Delsol G, Gascoyne RD, Harris NL, Pilieri M, Stein H. Aggressive B-cell lymphomas; a review based on the Workshop of the XI Meeting of the European Association for Hematopathology. Histopathol 2005;46;241-55.

  42. Ramsey AD, Smith WJ, Isaacson PG. T-cell-rich-B-cell lymphoma Am J Surg Pathol 1988;12:433-43.

  43. Nam-Cha SH, Roncador G, Sánchez-Verde L, et al. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte- predominant Hodgkin lymphoma. Am J Surg Pathol 2008;32:1252-7.

  44. De Leval L, Ferry J, Falini B Shipp M, Harris NL. Expression of bcl-6 and CD10 in primary mediastinal B-cell lymphoma. Evidence for derivation from germinal center B cell?. Am J Surg Pathol 2001;25;1277-82.

  45. Isaacson PG, Norton AJ, Addis BJ. The human thymus contains a novel population of B lymphocytes. Lancet 1987; 2:1488- 91.

  46. Calaminici M, Piper K, Lee AM, Norton AJ. CD23 expression in mediastinal large B-cell lymphomas. Histopathology 2004;45:619-24.

  47. Savage KJ, Harris NL, Vose JM, et al. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specifi ed: Report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-504.

  48. Vassallo J, Lamant L, Brugieres L, et al. Alk-positive anaplasticlarge cell lymphoma mimicking nodular sclerosis Hodgkin’s disease. Report of 10 cases. Am J Surg Pathol 2006;30:223- 9.

  49. Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006;1:375-404.

  50. Vetsika EK, Callan M. Infectious mononucleosis and Epstein- Barr virus. Expert Rev Mol Med 2004;6:1-16.

  51. Cohen JI. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases. Semin Hematol 2003;40:116-23.

  52. Kapatai G, Murray P. Contributions of the Epstein-Barr virus to the molecular pathogenesis of Hodgkin lymphomas. J Clin Pathol 2007;60:1342-9.

  53. Khalidi HS, Singleton TP, Weiss SW. Infl ammatory malignant fi brous histiocytoma: distinction form Hodgkin’s disease and non-Hodgkin’s lymphoma by panel of leukocyte markers. Mod Pathol 1997;10:438-44.

  54. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005;105:4553-60.

  55. Jaffe ES, Zarate-Osorno A, Medeiros LJ. The interrelationship of Hodgkin’s disease and Non-Hodgkin’s lymphomas –Lessons learned from composite and sequential malignancies. Sem Diag Pathol 1992;9:297-303.




2020     |     www.medigraphic.com